Our results demonstrate that CESC patients with high NUSAP1 expression were enriched in the G2M checkpoint, MYC targets, and breast cancer ZNF217, which are closely related to the early onset of cancer and the risk of tumor progression and metastasis. Here, ZNF217 is linked to breast cancer.